Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DPTX3496
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DPTX3496 Chosen for Colorectal, Breast, and Lung Cancer Treatment
Details : DPTX3496 is an oral, small molecule condensate modulator targeting beta catenin to address Wnt-driven colorectal cancer (CRC), triple-negative breast cancer (TNBC), and non-small cell lung cancer
Product Name : DPTX3496
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : DPTX3496
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DPTX3186
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : ConcertAI
Deal Size : Undisclosed
Deal Type : Partnership
Dewpoint and ConcertAI Start Translational Oncology Partnership First Phase
Details : The partnership aims to advance Dewpoint's preclinical product DPTX3186 a c-mod that inhibits beta-catenin oncogenic function. It is being evaluated for the treatment of cancers.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : DPTX3186
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : ConcertAI
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Mitsubishi Tanabe Pharma
Deal Size : $480.0 million
Deal Type : Collaboration
Dewpoint & Mitsubishi Partner for ALS Small Molecule Condensate Modulator
Details : The collaboration of Dewpoint with MTPC to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Mitsubishi Tanabe Pharma
Deal Size : $480.0 million
Deal Type : Collaboration
Lead Product(s) : DPTX3186
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dewpoint Nominates DPTX3186 for Wnt-Driven Cancer Treatment Development
Details : DPTX3186 is a c-mod that acts through a novel MOA to sequester beta-catenin into nuclear depot condensates. It is being evaluated for Wnt-driven colorectal cancer, and gastrointestinal cancer.
Product Name : DPTX3186
Product Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2024
Lead Product(s) : DPTX3186
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Bayer AG
Deal Size : $424.0 million
Deal Type : Licensing Agreement
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
Details : Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutations
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
October 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Bayer AG
Deal Size : $424.0 million
Deal Type : Licensing Agreement
Lead Product(s) : C-mods-based Therapy
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Target ALS Foundation
Deal Size : Undisclosed
Deal Type : Funding
Dewpoint Receives ALS Grant For Second Time To Develop ALS Therapies
Details : The grant will support the in vivo development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
August 26, 2024
Lead Product(s) : C-mods-based Therapy
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Target ALS Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Condensate Modifying Drug
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : ALS Association
Deal Size : Undisclosed
Deal Type : Funding
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS
Details : The grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in amyotrophic lateral sclerosis animal model.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Condensate Modifying Drug
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : ALS Association
Deal Size : Undisclosed
Deal Type : Funding
Details : Under the partnership, Chemify and Dewpoint will develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify's programmable chemistry platform against condensate targets of interest in Dewpoint's oncology and neurodeg...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $745.0 million
Deal Type : Partnership
Details : The partnership brings together Novo Nordisk's global leadership in treating diabetes and metabolic diseases with Dewpoint's groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
March 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $745.0 million
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Pfizer Inc
Deal Size : $239.0 million
Deal Type : Collaboration
Details : Dewpoint Therapeutics and Pfizer will collaborate for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 06, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Pfizer Inc
Deal Size : $239.0 million
Deal Type : Collaboration